Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT04807712
Recruiting Observational

Pediatric Pertussis in Ambulatory Settings

NCT04807712 · tracked via the Priya Life Science France tracker
Sponsor
Association Clinique Thérapeutique Infantile du val de Marne
Phase
Observational
Started
2001-05-30
Last updated
2024-02-08

Condition(s) studied

Pertussis/Whooping CoughChildren, OnlyAmbulatory

Investigational drug(s) / intervention(s)

non interventional study

Study summary

Since 2002, Whooping cough surveillance in pediatric private practice has been set up in France. The results of the first years, 2002-2006, have confirmed the effectiveness of the Pertussis whole-cell (Pw) vaccine and in particular the duration of protection of 9/10 years. After evaluating cases in children vaccinated with Pw vaccines, the study aims today to analyze cases in children vaccinated with Pertussis acellular (Pa) vaccines used since 2002/2003 and to assess, on an outpatient basis, the impact of new vaccine recommendations in France (in 2013, introduction of a 2 + 1 schedule - 8 weeks, 4 months and a 11-month recall - and a 6-year recall, and in 2014, update in the recommendations of exams to be prescribed based on the child's age and vaccination status).

Eligibility

Sex
ALL
Min age
1 Day
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: * All children under 18 years old with a pertussis diagnosis is suspected and a biological exam is requested Exclusion Criteria: * children without symptoms with a household confirmed case * cases for which the pertussis diagnosis was not suspected by the pediatrician

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
ACTIV Créteil France Recruiting

More Association Clinique Thérapeutique Infantile du val de Marne trials in France

Pediatric and Ambulatory Research in Infectious Diseases Recruiting
National, Non Interventional Study of Invasive Pneumococcal Disease in Children and Newborns Recruiting
CommunautAry Pediatric bacteRial Infection in Intensive CarE Unit Recruiting
Bacteriological Evaluation of Children With Otorrhea Recruiting
Nasopharyngeal Carriage of S. Pneumoniae Recruiting

Other trials for the same condition

Outpatient Management of Tonsillectomy in Adults Active, not recruiting
Nasopharyngeal Carriage of S. Pneumoniae Recruiting
RSV Burden in Outpatient and Hospital Settings Recruiting
National Bacterial Meningitis Study in Children and Newborns Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04807712 on ClinicalTrials.gov ↗ ← All trials in France